|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||36.00 / 46.38|
St. Jude shares deserve to be higher ahead of the merger with Abbott Labs. Here's why.
Shares of the medical-device giant were climbing after unveiling strong earnings.
Political pressure is weighing on drug and medical device stocks including Abbott Labs and St. Jude, says Jim Cramer.
Miles White also reiterated that Abbott Laboratories has no plans to divest of its diabetes business. He still believes in Alere over the long term.
The medical device maker responded to allegations that its devices could be hacked during its third quarter earnings call.
Abbott Labs ABT) on Wednesday morning posted earnings that were above analysts' expectations for the 2016 third quarter.
U.S. stock futures turn mixed; Yahoo!'s adjusted earnings top forecasts but revenue falls 14% in the third quarter; Intel guides to fourth-quarter revenue below consensus.
They plan to sell portions of their vascular closure and electrophysiology businesses to Japan's Terumo Corp. for $1.12 billion.
- The agreement is an important step toward completion of Abbott's acquisition of St. Jude Medical
On Wednesday, Abbott (ABT) is expected to post third-quarter earnings and revenue that are higher than a year ago.
Some of our favorite stocks will report earnings this week; here's a look at what else Jim Cramer is keeping an eye on.
Political anxiety, weak earnings and the dread of rising interest rates are weighing on markets. Here's how to protect your portfolio.
Cramer says his game plan is all about earnings, when the fundamentals control the market.
Illumina fell 24% on news that it was cutting revenue guidance.
St. Jude's warning about battery risks in its implanted heart devices are big but will likely not disrupt its deal with Abbott Labs.
St. Jude Medical's defibrillators are having problems with batteries, but this likely won't affect Abbott Laboratories' acquisition of the medical device maker.
Abbott agreed to acquire St. Jude Medical for $25 billion, or about $85 per share. But with an alert on a major St. Jude product, what now? Cramer wonders.
Keep an eye on Eaton Vance and these 6 notable dividend must-own dates.
A KeyBanc Capital Markets analyst increases his price target on the stock to $221 from $199.
The FDA today authorized Abbott's (ABT) FreeStyle Libre Pro system, which is used to continually monitor diabetic patients' glucose levels.
Health care companies will likely continue their battle over a soured merger in Delaware court.
- FREESTYLE LIBRE PRO IS A CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM DESIGNED TO PROVIDE A CLEAR, VISUAL SNAPSHOT OF A PATIENT'S GLUCOSE LEVELS, TRENDS AND PATTERNS FOR UP TO 14 DAYS
The most recent short interest data has been released for the 09/15/2016 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
- NEW RESEARCH SHOWS THAT MALNUTRITION ASSOCIATED WITH DISEASE INCREASES MEDICAL SPENDING BY MORE THAN $1 BILLION YEARLY IN CALIFORNIA, NEW YORK, TEXAS AND FLORIDA
MYOPLEX® KETOGENIC DELIVERS THE RIGHT AMOUNT OF NUTRIENTS NEEDED TO SUPPORT A KETOGENIC REGIMEN AND HELP ATHLETES ACHIEVE THEIR BODY AND PERFORMANCE GOALS